A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It

A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It

PR Newswire

RENO, Nev., July 7, 2026

Issued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ: CNXU) completed the P.R.O.O.F phase of its CXU preclinical program, the evidence base behind a focused first move into a roughly $11 billion medical aesthetics injectable market, an opening the company argues today's tools were never built to reach.RENO, Nev., July 7, 2026 /PRNewswire/ -- Equity Insider News Commentary, The weight-loss drug boom is one of the defining medical stories of the decade, and its second-order effects are only beginning to reshape adjacent markets. As millions of patients lose significant weight on GLP-1 therapies, they are encountering a form of facial and body volume loss the existing aesthetic toolkit was never built to restore, and the market to solve it is growing fast. Against that backdrop, Conexeu Sciences Inc. (NASDAQ: CNXU) has completed a preclinical milestone it frames as the evidence base for a focused entry into medical aesthetics, positioning itself as an early mover in a tissue-restoration gap the current injectable toolkit does not reach.